Company / Gross Margin
AXIM BIOTECHNOLOGIES, INC. Gross Margin History
FY2015-FY2018 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Gross Margin
95.7%
FY2018
5-year range
-227.5% / 95.7%
FY2015-FY2018
Trend
+865.2%
vs FY2017
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Gross Margin changed +865% YoY in FY2018, a notable deviation from the 3-year average annual change of -2629%.
Based on SEC 10-K filings.
95.7% in FY2018 with a 3-year CAGR of +98.2%.
Improved from -227.5% to 95.7% over the past 2 years.
Gross Margin over time
Growth rates
- 3-Year Change
- +98.2pp
- 5-Year Change
- -
- 10-Year Change
- -
Key checks
Key Insights
- In FY2018, gross margin increased 865.2% year-over-year.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -18.18 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Gross MarginValue | YoY GrowthYoY |
|---|---|---|
| FY2023 | - | - |
| FY2022 | - | - |
| FY2018 | 95.7% | +865.2% |
| FY2017 | 9.9% | +104.4% |
| FY2016 | -227.5% | -8857.9% |
| FY2015 | -2.5% | - |
| FY2013 | - | - |
| FY2012 | - | - |
| FY2011 | - | - |
As of FY2018 · SEC 10-K · Updated Jun 29, 2026